StockData

Kazia Therapeutics vs Silo Pharma

KZIA and SILO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KZIA and SILO compare

Silo Pharma grew revenue faster over the last twelve months (−25.0% versus −98.2% for Kazia Therapeutics).

Silo Pharma keeps more of each dollar of sales as profit, with a net margin of −8270% compared with −49291% at Kazia Therapeutics.

Silo Pharma scores higher on the StockData Score (2 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKZIASILO
Size and price
Market cap–$2.7M
Share price$5.31$1.71
Change, 1 year−15.3%−72.4%
Change, 5 years−98.9%−98.8%
Beta (5Y)4.082.90
Employees143
StockData Score
Total score12 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score11
Dividend score00
Valuation
P/S–50.2×
P/B–0.6×
Growth
Revenue growth (TTM)−98.2%−25.0% (better)
Revenue growth, 5Y average–12.0%
Profitability
Gross margin–−14.8%
Operating margin–−8250%
Net margin−49291%−8270% (better)
Return on equity–−91.2%
Financial health
Interest coverage–−112.0×
Current ratio2.875.36 (better)
Altman Z-score–−5.17
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.45%9.0%
Held by insiders0.29%13.8%
Insider net buying, 12 months–$2.1K
Superinvestors holding1–
Short interest, % of float–1.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.